title: Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children.
abstract: Asymmetric dimethylarginine (ADMA) is a nonselective nitric oxide (NO) synthase inhibitor associated with cardiovascular and metabolic disorders. In several prospective and cross-sectional studies, ADMA has evolved as a marker of cardiovascular risk. However, there is limited information on this serum marker in young people, particularly in those with obesity, type 1 diabetes (DM1) and type 2 diabetes (DM2). We investigated ADMA concentrations in children and adolescents with hyperglycemia as compared with healthy age- and sex-matched individuals. The subjects were 21 simple obesity [male 13, female 8; aged 11.7±4.3 years], 18 with DM1 [male 4, female 14; aged 12.9±4.2 years, duration of disease 3.4±2.1 years], 10 with DM2 [male 5, female 5; aged 13.9±3.4 years, duration of disease 2.8±1.4 years] and 21 controls [male 12, female 9; aged 11.1±2.7 years]. ADMA levels were analyzed in a cross-sectional study. Concentrations of serum ADMA were determined using an enzyme-linked immunosorbent assay. Circulating levels of ADMA were significantly lower in subjects with DM1, DM2 or obesity. In all subjects, ADMA levels were inversely correlated with glycated hemoglobin A1c concentrations (r=-0.401, p=0.0003) and serum glucose levels (r=-0.341, p=0.0023). Low circulating ADMA levels are directly associated with glucose levels, suggesting that ADMA production is suppressed in childhood in order to compensate and protect vasculopathy due to hyperglycemia.
authors.affiliation: Department of Pediatrics, Kawachi General Hospital, Higashi-Osaka 578-0954, Japan.
authors.forename: Junji
authors.initials: J
authors.lastname: Takaya
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tanabe
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kuroyanagi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kaneko
mesh_terms: D000293:Adolescent; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D002648:Child; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000628:therapy; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control; D058065:Diabetic Cardiomyopathies / Q000453:epidemiology / Q000517:prevention & control; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000097:blood* / Q000150:complications / Q000209:etiology / Q000517:prevention & control; D007564:Japan / Q000453:epidemiology; D008297:Male; D063766:Pediatric Obesity / Q000503:physiopathology* / Q000628:therapy; D012306:Risk
chemical_list: D001120:Arginine; D015415:Biomarkers; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human; C018524:N,N-dimethylarginine